CMS Open Payments · Program Year 2024
RxSight Inc
RxSight Inc reported $14,513,951.99 across General Payments, Research, and Ownership to 7,552 physicians and teaching hospitals across 9,080 transactions.
- $14.5M
- All-tracks total
- 9,080
- Transactions
- 7,552
- Recipients
- +$9.2M
- General Payments vs PY2023
RxSight Inc reported $14,513,951.99 across all CMS Open Payments tracks (General + Research + Ownership) to 7,552 physicians and teaching hospitals in Program Year 2024 - ranking #130 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $11,077,231.54, averaging $1.9K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer rxsight-inc RxSight Inc
$14.5M · #130/1,925 · 0.1% industry · PY2024
- TOT $14.5M
- RANK #130
- SHARE 0.1%
- TXN 9,080
- RCP 7,552
- CAT 7
- GEN $11.1M
- ΔGEN +$9.2M
- TOP1 70.9%
- PY 2024
Volume peers
Nearest volume peer: Otsuka America Pharmaceutical, Inc. ($14.5M)
RxSight Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
RxSight Inc's CMS-reported General Payments increased by $9.2M (+495.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: RXSIGHT INCPY2023: RXSIGHT INCPY2024: RxSight Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,858,835.93
- PY2024
- $11,077,231.54
What the Data Shows for RxSight Inc
Averaging $1.6K per transaction and $1.9K per recipient, RxSight Inc's Program Year 2024 total comes to $14,513,951.99 across 9,080 transactions and 7,552 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #130 of 1,925 companies, representing 0.1% of all industry payments reported nationwide for the year.
15 transactions worth $10.0M make "Compensation for Services Other Than Consulting" the top general-payment category in the 7-category breakdown below, 90.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads RxSight Inc's 7-category general-payment breakdown at $10.0M, 90.0% of the reported total.
RxSight Inc reports 7 general-payment categories - the top three are Compensation for Services Other Than Consulting (90.0%), Consulting Fee (5.7%), and Food and Beverage (3.6%). The remaining 4 categories make up 0.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How RxSight Inc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $10.0M | 15 | 90.0% |
| Consulting Fee | $636.2K | 248 | 5.7% |
| Food and Beverage | $393.8K | 6,821 | 3.6% |
| Gift | $40.6K | 41 | 0.4% |
| Education | $29.0K | 29 | 0.3% |
| Honoraria | $10.4K | 380 | 0.1% |
| Travel and Lodging | $2.6K | 18 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $9,495,612.56 (85.7%) of $11,077,231.54 in this company's General Payments records across 4,416 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for RxSight Inc
The five named recipients with the highest reported General Payments from this company
- 1
Daniel Schwartz
$7,851,985.15 across 5 reported transactions
- 2
Daniel Durrie
$726,000.65 across 2 reported transactions
- 3
Vance Thompson
$362,314.62 across 7 reported transactions
- 4
Stephen Slade
$357,959.24 across 8 reported transactions
- 5
Tamara Fountain
$197,352.90 across 14 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as RxSight Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about RxSight Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with RxSight Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
NovApproach Spine, LLC
Swedish Orphan Biovitrum Ab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Roche Diagnostics Operations, Inc.
Argenx US, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.